Southeast Asia - Regenerative Medicine of South East Asia (RSEA)
India - Regenerative Medicine of India (RMIN)
Korea - Regenerative Medicine of Korea (RMKO)
Japan - Regenerative Medicine of Japan (RMJP)
ANZ - Regenerative Medicine of ANZ (RANZ)
which acquired the rights to market all of Zhittya’s biological drugs in Europe.
Regenerative Medicine of Europe
Regenerative Medicine of China
for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period
In addition to these five publicly announced agreements, Zhittya is currently negotiating five additional marketing partnerships which will allow its drugs to be sold and distributed by its partners throughout the rest of the world, including the regions of South-East Asia, India Subcontinent, Korea, Japan and Australia/New Zealand.
Regenerative Medicine of MENA
which acquired the rights to market all of Zhittya’s biological drugs in the Middle East and North Africa.
Zhittya’s primary corporate function will be overseeing the clinical development of different formulations of FGF-1 for unique medical indications. Through USA FDA-authorized clinical studies, it will seek to advance these drugs up to and through the US FDA approval process.
Regenerative Medicine of Latin America
which acquired the rights to market all of Zhittya’s biological drugs in Latin America.
WUND Healing BioPharmaceuticals Inc.
which acquired the rights to market all of Zhittya’s biological drugs in the U.S. and Canada.